Quick Recap
Infectious Diseases System, Protocol 5/6. Covers neutropenic fever, transplant recipients, HIV/advanced HIV, and the pneumonia differential across immunocompromised states.
1. General Principles
Immunocompromised patients are at increased risk for BOTH severe presentations of common infections AND classic opportunistic pathogens — the specific pathogen risk depends on the TYPE, DURATION, and DEGREE of the immune defect (physical barrier, innate, or adaptive immunity impairment). Classical signs/symptoms of infection (fever, leukocytosis) are FREQUENTLY ABSENT in this population — a muted inflammatory response can also disguise localizing symptoms (abdominal pain, pulmonary infiltrates) and delay identification of an infectious focus. A high level of clinical suspicion, not reliance on classic findings, is essential, and diagnosis/management is often best accomplished with early infectious disease consultation given the complexity.
Repeated antimicrobial exposure (prophylactic or therapeutic) in this population increases the incidence of multidrug-resistant pathogen infection — factor this into empiric coverage decisions.
2. Neutropenic Fever
Severe neutropenia: ANC <500 cells/mm3, OR an anticipated decline to <500 over the next 48 hours.
Neutropenic fever definition: a SINGLE temperature >=38.3C (101F), OR a persistent temperature >=38.0C (100.4F) for MORE THAN 1 HOUR, in a severely neutropenic patient.
Prolonged (>7 days) and more severe neutropenia both increase bloodstream/serious infection risk.
>50% of neutropenic fever patients are ultimately found to have an established or occult infection — this is a MEDICAL EMERGENCY requiring RAPID empiric broad-spectrum antibiotic administration (target within 1 hour, mirroring septic shock urgency) AND a parallel infectious workup, not sequential.
Specific neutropenia-associated diagnoses beyond standard ICU infections (pneumonia, UTI, bacteremia):
- Chemotherapy-induced mucositis increases infection risk at sinuses, oropharynx, and GI tract
- Invasive fungal sinusitis: the most FEARED mucositis-related complication given high morbidity/mortality — low threshold for ENT evaluation/imaging in a neutropenic patient with sinus symptoms
- Neutropenic enterocolitis (typhlitis): a NECROTIZING infection of the cecum, can extend to terminal ileum/ascending colon -> risk of perforation, peritonitis, hemorrhage, sepsis — consider in any neutropenic patient with abdominal pain, and image (CT) accordingly; a distinct, must-not-miss diagnosis analogous in severity to necrotizing fasciitis but in the GI tract
- Bacterial translocation across damaged mucosal membranes can precipitate serious BSI with Enterococcus, Candida, Enterobacteriaceae, or other gram-negatives
3. Fungal Infections in Neutropenia/Immunocompromise — Key Organisms
Yeasts: Candida spp. and Cryptococcus spp. most commonly encountered; Pneumocystis jirovecii causes multifocal pneumonia, classically in advanced HIV but also relevant in other severe immunosuppression.
Dimorphic fungi (historically "endemic fungi"): Blastomyces, Histoplasma, Coccidioides, Penicillium — geographic exposure is an important diagnostic clue, but increased travel/climate change mean these are increasingly diagnosed OUTSIDE their traditional ranges; a lack of classic geographic exposure does NOT rule out infection.
- Blastomycosis: can rarely present as diffuse pneumonitis/ARDS with >50% mortality in that presentation, with most deaths occurring in the FIRST FEW DAYS of treatment — consider in community-acquired ARDS with a compatible travel/residence history; serology is NOT useful for diagnosis (requires histology/culture); urine antigen 93% sensitive/79% specific, with cross-reactivity to Histoplasma antigen testing causing diagnostic uncertainty
- Coccidioidomycosis: hyperendemic to southwestern US/Central/South American deserts ("Valley Fever"); coccidioidal meningitis should be suspected with persistent headache/fever after recent pneumonia; fluconazole first-line, meningitis in immunocompromised patients may need LIFELONG therapy if the immunocompromise is irreversible
- Penicillium marneffei: important HIV-associated pathogen in hyperendemic Southeast Asia, presents similarly to disseminated histoplasmosis/TB, can mimic bacterial sepsis in severe presentations
Monomorphic molds — invasive aspergillosis is the most commonly encountered invasive mold:
- Risk factors: prolonged neutropenia (>10 days), HSCT, solid organ transplant, corticosteroid/immunosuppressive therapy, advanced HIV, chronic granulomatous disease
- Classic triad for invasive pulmonary aspergillosis: fever, pleuritic chest pain, dyspnea, usually with neutropenia; imaging may show nodules +/- cavitation, possible fungal ball
- Angioinvasion and dissemination carry poor prognosis — direct vascular invasion causes thrombosis/tissue infarction/necrosis
- Serum galactomannan performance is highly variable by pathogen and host — interpret with current literature/local validation in mind rather than treating as a uniformly reliable rule-out test
- Disseminated Fusarium classically associated with onychomycosis as a portal of entry in neutropenic patients; involves the lung in ~50% of cases; skin lesions can be localized cellulitis or disseminated papular/nodular lesions with central necrosis, with mortality up to 90% in persistently neutropenic disseminated disease — a new rash in a persistently febrile neutropenic patient should prompt fusariosis consideration
4. Solid Organ Transplant (SOT) Recipients
Infectious risk timeline generally shifts from opportunistic pathogens (early, high-immunosuppression period) to community-acquired infections (after ~6 months) as maintenance immunosuppression is typically reduced — BUT patients requiring ongoing aggressive immunosuppression or treatment for acute rejection remain susceptible to opportunistic pathogens regardless of time since transplant.
SOT-specific structural/vascular complications can mimic or complicate infectious presentations (see the ICU Syndromes in SOT table): hepatic artery thrombosis (acute -> sudden LFT rise, needs emergent surgical/endovascular repair; subacute/chronic -> bile leak/biliary sepsis, needs stenting + antibiotics + drainage), renal artery thrombosis, ischemic airway injury in lung transplant (bronchoscopy with debridement/stenting), and elevated PE risk (especially lung transplant recipients, who also have higher lung infarction risk).
5. Hematopoietic Stem Cell Transplant (HSCT) — Timeline-Based Pathogen Risk
Allogeneic HSCT carries higher infection risk than autologous (autologous patients share pre-engraftment risk but largely recover immune function after engraftment; allogeneic patients continue at risk, especially with chronic GVHD).
Phase | Timing | Key Pathogens |
Pre-engraftment | <3 weeks | Gram-positive bacteria, gram-negative bacteria, C. difficile, Candida, Aspergillus, Fusarium, Mucormycetes, HSV (if seropositive), respiratory viruses |
Early post-engraftment | 3 weeks-3 months | Legionella, Listeria, Nocardia, M. tuberculosis, NTM, Candida, Aspergillus, Fusarium, Mucormycetes, PJP, CMV, EBV, HHV-6/7, VZV, respiratory viruses, BK polyomavirus |
Late post-engraftment | >3 months | Toxoplasma, Strongyloides, Cryptosporidium, encapsulated bacteria (S. pneumoniae, H. influenzae, N. meningitidis), Nocardia, dimorphic mycoses, CMV, EBV, VZV, BK/JC polyomavirus, Parvovirus B19; if chronic GVHD present, ALSO consider pre-engraftment and early post-engraftment organisms — GVHD effectively resets the risk clock backward |
Focused history essential for narrowing the differential: transplant type, time since transplant, chronic GVHD presence, immunosuppression regimen, antimicrobial prophylaxis, age, travel history, occupation/hobbies.
6. HIV / Advanced HIV
"Advanced HIV" is the preferred contemporary terminology over historical "AIDS" nomenclature given associated stigma.
CD4+ interpretation caveat: medications, infection, or other conditions causing lymphocytosis/lymphopenia can FALSELY elevate or depress the absolute CD4+ count — CD4+ PERCENTAGE is often more useful/reliable for intensivists since the proportion of lymphocytes that are CD4+ remains roughly stable regardless of total lymphocyte count fluctuations. CD4+ percentage <14% corresponds to an absolute count <200 — defines advanced HIV.
Pulmonary infection differential by CD4+ threshold:
- Any CD4+: bacterial pneumonia (S. pneumoniae, H. influenzae, increasingly S. aureus), M. tuberculosis
- CD4+ <200: ADD Pneumocystis jirovecii pneumonia (PJP), dimorphic mycoses, Toxoplasma
- CD4+ <50: ADD Mycobacterium avium complex (MAC), CMV, VZV
PJP: prevalence rises dramatically below CD4+ 200; prophylactic antimicrobial use does NOT exclude the diagnosis — do not rule out PJP simply because the patient is on prophylaxis. Adjunctive corticosteroids reduce mortality in SEVERE PJP specifically (PO2 <60 mmHg and A-a gradient >45) — a specific, evidence-supported steroid indication distinct from most other pneumonia contexts.
Adrenal insufficiency can complicate management, associated with disseminated CMV, TB, histoplasmosis, Kaposi sarcoma, lymphoma, and pentamidine treatment — maintain a low threshold to consider (see Adrenal Crisis protocol, Endocrine System) in an advanced HIV patient with unexplained hypotension/shock.
CNS infection differential by CD4+ threshold:
- Any CD4+: bacterial meningitis, Listeria, HSV
- CD4+ <100: Toxoplasma gondii encephalitis risk rises significantly — fever, headache, altered mental status, focal deficits, seizures; ring-enhancing lesions on contrast CT/MRI are classic, though the differential for ring-enhancing lesions also includes bacterial abscess, cryptococcoma, CNS aspergillosis, and syphilitic gummas (see Encephalitis protocol, Neurology System, for the full ring-enhancing-lesion differential)
- CD4+ <50: Cryptococcus neoformans, CMV, EBV-associated lymphoma, VZV, JC polyomavirus (progressive multifocal leukoencephalopathy)
7. Pneumonia Differential by Host — Reference Table
Host | Key Pathogens |
Immunocompetent CAP | S. pneumoniae, H. influenzae, M. catarrhalis, Mycoplasma, Legionella, Chlamydia pneumoniae, MRSA, influenza/other respiratory viruses |
HAP/VAP | MRSA, Pseudomonas, Klebsiella, Acinetobacter, Stenotrophomonas, Legionella |
Neutropenia | Any of the above PLUS Aspergillus, (rarely) Candida |
Advanced HIV | Any of the above PLUS PJP, M. tuberculosis, Histoplasma, other fungi |
SOT/BMT | Any of the above, varying by timing relative to transplant (see Section 5 table) |
Cystic fibrosis | H. influenzae (early), S. aureus, Pseudomonas, Burkholderia cepacia |
8. Immediate Stabilization (ABCDE)
Circulation: treat as septic shock if hemodynamically unstable, applying full Septic Shock protocol principles — immunocompromised patients can decompensate rapidly and with less overt warning (muted inflammatory response) than immunocompetent patients.
Checklist:
9. Organ Support
Broad-spectrum empiric antibiotics (neutropenic fever protocol-level urgency); antifungal therapy per organism/syndrome (see dosing tables in the Tumor Lysis Syndrome and general antifungal references); adjunctive corticosteroids for severe PJP specifically; standard ICU supportive care; source control (surgical) for neutropenic enterocolitis with perforation/hemorrhage.
10. Consultation Matrix
Consultation | Trigger | Timing |
Infectious Disease | All significant infections in immunocompromised hosts | Immediate |
Hematology/Oncology | Neutropenic fever, underlying malignancy management | Immediate |
Transplant Medicine/Surgery | SOT/HSCT-associated infection or structural complication | Immediate |
Surgery | Neutropenic enterocolitis with perforation/hemorrhage risk | Immediate if suspected |
11. Monitoring Framework
Serial temperature/clinical status (given blunted inflammatory signs), ANC trend (neutropenic fever), CD4+ percentage trend (HIV), serial imaging for evolving fungal/mold infection, drug level monitoring for antifungal/immunosuppressive agents, GVHD status reassessment in HSCT recipients.
12. Complications
Septic shock, invasive fungal sinusitis, neutropenic enterocolitis with perforation, disseminated fungal infection (aspergillosis, fusariosis), CNS opportunistic infection, adrenal insufficiency (advanced HIV), graft complications (SOT structural issues). Prevention: rapid empiric therapy for neutropenic fever, prophylaxis where indicated (though awareness that prophylaxis doesn't exclude breakthrough infection), close transplant-timeline-informed surveillance. Rescue: source control surgery for enterocolitis/perforation, escalating antifungal therapy for invasive mold disease, adjunctive steroids for severe PJP.
13. Escalation & De-escalation
Escalate: neutropenic fever criteria met -> immediate empiric antibiotics; invasive fungal infection suspected/confirmed -> targeted antifungal therapy, consider surgical debridement for angioinvasive disease; CNS mass lesion in advanced HIV -> empiric toxoplasmosis treatment trial or biopsy per CD4+ context.
De-escalate: ANC recovering, afebrile, source identified/controlled -> narrow antimicrobial coverage per culture/pathogen-specific results, transition to prophylactic dosing where appropriate.
14. ICU Discharge Criteria
Hemodynamically stable, ANC recovering or growth factor support established, source of infection identified and controlled, antimicrobial regimen narrowed to a definitive course, transplant/oncology follow-up arranged.
15. Documentation & Medicolegal Checklist
16. Key Guidelines
Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: IDSA 2010 update. Clin Infect Dis. 2011;52(4):e56-e93.
17. Controversies
Optimal empiric antifungal threshold/timing in persistently febrile neutropenic patients without a confirmed source remains debated (empiric vs pre-emptive, biomarker-driven strategies). Serum galactomannan and beta-D-glucan test performance variability across pathogens/hosts limits their standalone diagnostic reliability, and interpretation guidance continues to evolve. Adjunctive corticosteroid use in severe PJP is well-supported, but its role in other opportunistic pulmonary infections in this population is far less established.
18. References
- Mazi PB, Liang SY. Infections in the Immunocompromised Host. Washington Manual of Critical Care, 4th ed, 2025 (Ch. 43).
- Mazi PB, Spec A. Invasive Fungal Infection. Washington Manual of Critical Care, 4th ed, 2025 (Ch. 42).
- Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: IDSA 2010 update. Clin Infect Dis. 2011;52(4):e56-e93.
- Hiemenz JW. Management of infections complicating allogeneic hematopoietic stem cell transplantation. Semin Hematol. 2009;46(3):289-312.
See also: Sepsis/Septic Shock (Infectious Diseases System), Tumor Lysis Syndrome (Renal System), Adrenal Crisis (Endocrine & Metabolic System), and Encephalitis (Neurology System) for closely related management overlap.